<DOC>
	<DOCNO>NCT00776594</DOCNO>
	<brief_summary>The purpose research study assess efficacy antiangiogenic therapy ( bevacizumab ) androgen deprivation versus androgen deprivation alone time minimal systemic disease ( base rise PSA without metastasis ) .</brief_summary>
	<brief_title>Androgen Deprivation Therapy +/- Bevacizumab PSA Recurrence Prostate Cancer After Definitive Local Therapy</brief_title>
	<detailed_description>- Participants randomize one two study group . The first group receive Androgen Deprivation Therapy ( ADT ) plus bevacizumab . The second group receive ADT alone . - For Androgen Deprivation therapy either ( treat physician discretion ) leuprolide goserelin acetate ( give injection ) every 3 month total 6 month . Bicalutamide also take orally daily total 6 month . - Bevacizumab give intravenously every three week total 8 infusion 6 month . - Participants evaluate every 7-9 week vitals , physical exam , PS , laboratories include PSA testosterone .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<mesh_term>Estrogens , Conjugated ( USP )</mesh_term>
	<criteria>History biopsy document prostate cancer ( Gleason score ) Past treatment prostatectomy without salvage prostate/pelvic radiation primary radiation ( external beam brachytherapy ) If past prostatectomy , pathologic stage great T13 , N1 , M0 PSA recurrence PSAdt &lt; 18 month . There minimum PSA prostatectomy patient . For patient treated primary radiation therapy PSA great 2.0 ng/ml No evidence recurrent disease exam , bone scan , CT/MRI abdomen/pelvis CXR Prior ADT allow &lt; 6 month testosterone recover within 50 unit ( ng/dl ) normal range ECOG Performance status 01 Absolute neutrophil count &gt; 1,500 Platelet count &gt; 100,000 Hg &gt; 8g/dl No history bleeding thromboses within last 12 month require medical intervention History cancer within 5 year , prostate cancer nonmelanoma skin cancer Medical condition require concomitant corticosteroid Active infection Prior chemotherapy allow &lt; 6 cycle &gt; 6 month prior study entry Documented local recurrence metastatic prostate cancer Inability comply study and/or followup procedure Life expectancy le 2 year Current , recent ( within 4 week first infusion study ) , plan participation experimental drug study Genentechsponsored bevacizumab cancer study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Androgen deprivation therapy</keyword>
	<keyword>ADT</keyword>
	<keyword>bevacizumab</keyword>
</DOC>